SKELID (nda020707)- (EQ 200MG BASE)

Generic Name	TILUDRONATE DISODIUM	Innovator	SANOFI AVENTIS US
Dosage	EQ 200MG BASE
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2010-Jan-30	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	SKELID is indicated for treatment of Paget's disease of bone (osteitis deformans).

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 200MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of SKELID